Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Frequently asked questions
What sector does Kura Oncology Inc (KUR) operate in?
Kura Oncology Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kura Oncology Inc (KUR) current stock price?
As of the latest data, Kura Oncology Inc stock price is €8.44, with a previous close of €8.46. Kura Oncology Inc lost -€0.02 in the last trading session, representing a -0.24% loss.
What is Kura Oncology Inc (KUR) current market capitalization?
Kura Oncology Inc market cap is approximately 750.83 million.
What is Kura Oncology Inc (KUR) Earnings Per Share (EPS)?
The trailing EPS is -€2.89.
What is Kura Oncology Inc (KUR) EBITDA?
Kura Oncology Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -59.19 million.
Does Kura Oncology Inc (KUR) pay dividends?
No. Kura Oncology Inc does not pay a dividend.
When is Kura Oncology Inc (KUR) next earnings report?
Kura Oncology Inc is expected to release its next earnings report on September 30, 2026.
What is Kura Oncology Inc (KUR) beta (volatility) score?
Kura Oncology Inc has a beta of 0.469, indicating lower volatility than the overall market.
